ClinicalTrials.gg
Status unknownNCT06362915Updated Apr 12, 2024

Analgesic Effect of Illiohypogastic & Ilioinguinal Nerve Block in TAVR - TF (Prospective Randomized Study)

A Phase 1/2 interventional study of Lidocaine and Bupivacain in Anesthesia, Local, sponsored by Ain Shams University. Status unknown at 2 sites in Egypt. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Ain Shams University · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2024), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2024, registered Apr 2024).
Phase
Phase 1/2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Sex
All
01

Study summary

The purpose of the study is to compare the effect of illiohypogastric and ilioinguinal nerve block with the local infiltration with lidocaine in patients undergoing TAVI

Read the detailed description

This prospective, randomized, double blinded study will take place at cardiothoracic academy, Ain Shams University hospitals, Cairo, Egypt. In this study, participants, care providers and outcomes assessors will be ignorant of the treatment allocation. The study will start after obtaining the ethical approval \& will continue for a 1 year. All patients will sign written informed consent before inclusion.

Patients fulfilling criteria for TAVI regarding age \& pathology of aortic valve will be included in the study.

Exclusion criteria:

Refusal of the patients, Patients with neurological disease (Disturbed conscious level or psychiatric illness) severe respiratory disease need mechanical ventilation or need respiratory support, coagulation abnormalities, infection at site of injection.

After confirming the diagnosis \& preoperative sizing of the valve by CT heart and then confirmation that no need for TEE guidance of the procedure, we will include 60 patients and then will be divided into two groups according to the technique of local anesthesia for the site of puncture.

Sample size calculation was done using G power program; setting power at 80% and α error at 5%, a sample size 52 patients undergoing transcatheter aortic valve implantation "TAVI" (26 patients receiving iliohypogastric with ilioinguinal nerve block and 26 patients receiving local infiltration with lidocaine) will be added to detect a statistically significant difference between the two groups as regard analgesic consumption, assuming a large effect size difference (dz=0.8)regarding Hasak et al.,2019. Patients will be randomly allocated into two equal groups each one made of 30 patients, the allocation ratio is 1:1 and the method of randomization will be computer generated randomized numbers, and it will be hidden in sealed opaque envelopes to conceal the allocation. The study will start after acquisition of ethical approval and expected to continue for a year.

  • Group (A): will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.
  • Group (B): will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivicane 0.25% by an experienced anesthesiologist. (9).

In both group all patients undergo preoperative assessment: Full history, examination \& investigations.

ECG, ECHO, CT heart and CT coronary angiography, LL venous \& arterial duplex, CBC, Kidney and liver functions, Coagulation profile \& carotid duplex.

Inside the catheterization room, for both groups after standard monitors and invasive hemodynamic monitors were applied (US guided arterial in left radial, CVC inserted in left IJV \& sheath in right IJV for pacemaker).

Then Dexmedetomidine started in both groups by 0.1 up to 0.5 mic/kg/hour without loading with continuous monitoring for the HR and BP .

Then the patients divided into two groups: group for local infiltration and group for ilioinguinal illiohypogastric nerve block.

During injection of local anesthesia in both group any hemodynamic changes (blood pressure and heart rate should be closely monitored and recorded during data collection.

TAVI procedure will be proceeded. All patients were sent to ICU for postoperative care. HR, MAP, Conscious level of the patient assessed every 5 minutes. Need for increments narcotics or Propofol recorded and collected at end of procedure.

A Study made in 2019 on the effect of illiohypogastric ilioinguinal nerve block in TAVI patient found that Ultrasound-guided II-IH nerve block produce better intraoperative analgesia and less analgesic consumption than local infiltration anesthesia in patients undergoing TAVI .

02

Conditions studied

  • Anesthesia, Local
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,930 studies on the registry; 433 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients fulfilling criteria for TAVI regarding age \& pathology of aortic valve will be included in the study.

Exclusion criteria

Exclusion Criteria:

Refusal of the patients, Patients with neurological disease (Disturbed conscious level or psychiatric illness) severe respiratory disease need mechanical ventilation or need respiratory support, coagulation abnormalities, infection at site of injection.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Group A:Lidocaine group

    will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%

    Drug: Lidocaine

  • Active comparator
    Group B:Bupivacaine group

    will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivicane 0.25% by an experienced anesthesiologist

    Drug: Bupivacain

Interventions

  • * Group (A) lidocaine : will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.

  • • Group (B),bupivacaine: will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist

06

What researchers measure

Primary outcomes

  1. Extra Demand of sedation

    Need for increments of narcotics or propofol will be recorded and collected at the end of the procedure.

    Time frame: All through procedure

Secondary outcomes

  1. Patient and surgeon satisfaction

    Patient satisfaction in form not complaining or asking for more analgesic or deepen anesthesia. Surgical satisfaction in form of quiet noncomplaining patient, hemodynamic stability

    Time frame: all through the procedure

07

Study locations

2 of 2 sites recruiting
  • maha sadek El Derh
    Cairo, Heliopolis 11721, Egypt
    Recruiting
  • Ain Shams University
    Cairo, Egypt
    • maha S elDerh, Ass.prof · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Jul 2024, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 12, 2024
StartActual
Jan 2, 2024
Primary completionEst.
Jul 15, 2024
CompletionEst.
Aug 30, 2024
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06362915
Responsible party
maha sadek El Derh (Assistant professor of Anesthesia, Ain Shams University) — Principal investigator
First posted
Apr 12, 2024
Start date
Jan 2, 2024
Primary completion
Jul 15, 2024 (estimated)
Completion
Aug 30, 2024 (estimated)
Last update
Apr 12, 2024

Study contacts

maha S El Derh, MD
Contact
mahasadek81@yahoo.com
01144866675
samar M Abd El Tawab, MD
Contact
01006236494

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Bupivacaine

Start the discussion